Firefly Neuroscience Inc. and Zeto Inc. have forged a strategic distribution agreement for the latter’s U.S. Food and Drug Administration (FDA)-cleared EEG headset devices, cloud platform and services, thereby expanding Firefly’s accessibility to healthcare providers and institutions.

The partnership will also integrate Firefly’s proprietary Brain Network Analytics (BNA) technology with Zeto’s advanced EEG platform, which is currently being used in more than 200 U.S. hospitals and neurology offices.
 
“This collaboration of two progressive technology companies represents a major step forward in addressing an unmet medical need in brain health,” Firefly CEO Jon Olsen said. “By combining Zeto’s innovative hardware with our proprietary BNA technology, this partnership will offer healthcare providers deeper insights into neurological conditions that will ultimately improve patient outcomes.”
 
Zeto’s EEG headsets—WR19 and Zeto ONE—are FDA-cleared, full-montage, and easy to use, making brain monitoring accessible across various clinical settings, including the intensive care unit, emergency department, hospital, office, and home. Supported by a cloud-based platform, Zeto offers nationwide monitoring and interpretation services by neurologists, along with artificial intelligence-powered seizure detection and video capabilities. As part of the distribution agreement, Firefly will offer Zeto’s devices and cloud services to its customers, allowing healthcare professionals to access, analyze, and store EEG data in real-time. The integration with Firefly’s BNA platform enables more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders.
 
“We are excited to partner with Firefly to offer customers more valuable tools, helping expand our user base and improving the value of EEG,” Zeto Founder/CEO Aswin Gunasekar stated. “By integrating Firefly’s BNA offering with Zeto’s EEG platform, we are able to advance our mission of positively impacting patients’ lives through transformative, user-friendly, and best-in-class solutions.”
 
Firefly is an artificial intelligence company developing solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a database of brain wave tests, securing patent protection, and achieving FDA clearance. The company is now launching BNA commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
 
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of more than 17,000 patients representing 12 disorders, as well as clinically normal patients. BNA, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate the kind of therapy and/or drug best suited to optimize outcomes.

Zeto Inc., a medical technology firm, advances EEG brain monitoring and diagnostics. Offering wearable devices and supported by a feature-rich cloud-based platform, Zeto provides nationwide monitoring and interpretation services rendered by neurologists, alongside AI-enabled detection for conditions such as seizures and epilepsy. Zeto plans to expand its capabilities in the future to recognize and manage conditions such as depression and traumatic brain injury.